DIANA Biotechnologies at the biggest biotech event in Europe: Medica 2024

DIANA Biotechnologies Showcases Innovations at MEDICA 2024

We proudly presented our latest advancements at MEDICA 2024, Europe’s largest biotech event. Our unique solutions across Diagnostics, Molecular Reagents, Monoclonal Antibody Development, and Drug Discovery Services, forged new partnerships and collaborations throughout the event!

Brand new products and unique solution for monoclonal antibodies

MEDICA 2024 was a perfect place to show our broad portfolio of products. Even though the trade fair is focused on diagnostics, we were able to meet a plenty of customers targeting molecular reagents for academic labs or custom development of antibodies. And that was a perfect chance for us to show our unique solutions.

We showcased the DBdirect™ and SuperSens solutions for our PCR and RT-PCR Mixes, offering unmatched sensitivity for different applications. We also presented our brand new products such as DBscript Reverse Transcriptase and DBscript cDNA Synthesis Kit with superfast protoclol.

In monoclonal antibody development, we demonstrated our expertise in addressing even the most challenging targets. Our unique DIANA technology allows us to detect with unprecedented affinity and selectivity. And how much time we need to develop your desired antibody? less than six months!

Expanding our drug discovery portfolio

During the last year we have launched the DIANA Kinase Panel and DIANA CDK Panel, innovative tools designed to accelerate the discovery of kinase inhibitors, a critical class of drugs in cancer and other diseases.

Last but not least we unveiled our advanced oncodiagnostic pipeline, featuring solutions like KRAS mutation detection and liquid biopsy technologies, alongside a superfast diagnostic solution for sepsis. Together with that we are working on our PCR solutions for detecting CMV and EBV viruses and in the near future we will market our thrombophilia kit!

Expanding Global Partnerships

Our presence at MEDICA 2024 was met with overwhelming interest from attendees, fostering numerous partnerships and collaborations. Different customers from various fields expressed strong enthusiasm for our solutions. And we are truly delighted about this! The event served as a platform for meaningful dialogues and we are looking forward for the next one!

Media contact:

Petr Kašík

E-mail: [email protected]

Tel: +420734513384

About DIANA Biotechnologies

DIANA Biotechnologies, a.s. is a Czech biotechnology company with strong in-house research and development. The company was founded in 2018 with the aim to develop applications of the patented DIANA technology in diagnostics and drug development. However, the company's portfolio is now significantly broader. It is currently targeting global markets in three main areas: 1) development and production of PCR products for diagnostics and life science, 2) development of proprietary original low molecular weight drugs and provision of services to the pharmaceutical sector, and 3) development of antibodies for diagnostics and therapeutics. In the field of molecular diagnostics, the company has become the largest Czech manufacturer of PCR tests for COVID-19 and other viral diseases and is now making its mark abroad thanks to its innovations in PCR diagnostics. The company is built on a team of top scientists with unique expertise in molecular biology, biochemistry, organic and medicinal chemistry, pharmacology and laboratory automation. DIANA Biotechnologies aims to become a multinational biotechnology company developing its own original diagnostics and pharmaceuticals. For more information about the company, please continue to www.dianabiotech.com